3rd Quarter - Report
THE MCMANUS GROUP for GILEAD SCIENCES, INC.
Firm
Client
Income
$70,000
Expenses
—
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program. S.1287 - Viral Hepatitis Testing Act of 2015
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
| BARRETT THORNHILL | — |
Medicare/Medicaid MMM
Federal program coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
| BARRETT THORNHILL | — |
Veterans VET
Access and reimbursement for HCV products
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
| BARRETT THORNHILL | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.